Secretary of the IPA's Tehran branch Mohammad Amin Qobadi emphasized on Wednesday that the Iranian pharmacists succeeded in developing the vaccine through the use of innovative technology along with the collaboration of the biotechnology industry elite.
The domestically-developed four-valent vaccine successfully passed all clinical trials years ago, Qobadi said, adding that the vaccine has got the approval of Iran’s Ministry of Health and Medical Education, as well as various physicians. This is the third year of production and consumption of the recombinant influenza vaccine in Iran, he noted.
According to this member of the Iranian Association of Manufacturers and Exporters of Medical Biotech, the influenza vaccines developed in other countries are being produced based on eggs, and they cost five dollars, but the recombinant influenza vaccine is sold for 65 dollars throughout the world.
Iranian specialists supply the $65 vaccine for less than $5, Qobadi said, calling for support for domestically developed vaccines by consumer associations.
4208**2050
Your Comment